<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e> risks for a person who has inherited a MUTYH mutation from only one parent (monoallelic mutation carrier) are uncertain </plain></SENT>
<SENT sid="1" pm="."><plain>Using the <z:hpo ids='HP_0003003'>Colon Cancer</z:hpo> Family Registry and Newfoundland Familial <z:hpo ids='HP_0003003'>Colon Cancer</z:hpo> Registry, we identified 2,179 first- and second-degree relatives of 144 incident <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) cases who were monoallelic or biallelic mutation carriers ascertained by sampling population complete <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> registries in the United States, Canada and Australia </plain></SENT>
<SENT sid="2" pm="."><plain>Using Cox regression weighted to adjust for sampling on family history, we estimated that the country-, age- and sex-specific standardized incidence ratios (SIRs) for monoallelic mutation carriers, compared to the general population, were: 2.04 (95% confidence interval, CI 1.56-2.70; p &lt; 0.001) for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>, 3.24 (95%CI 2.18-4.98; p &lt; 0.001) for <z:hpo ids='HP_0012126'>gastric cancer</z:hpo>, 3.09 (95%CI 1.07-12.25; p = 0.07) for <z:hpo ids='HP_0002896'>liver cancer</z:hpo> and 2.33 (95%CI 1.18-5.08; p = 0.02) for <z:e sem="disease" ids="C0476089" disease_type="Neoplastic Process" abbrv="">endometrial cancer</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Age-specific cumulative risks to age 70 years, estimated using the SIRs and US population incidences, were: for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>, 6% (95%CI 5-8%) for men and 4% (95%CI 3-6%) for women; for <z:hpo ids='HP_0012126'>gastric cancer</z:hpo>, 2% (95%CI 1-3%) for men and 0.7% (95%CI 0.5-1%) for women; for <z:hpo ids='HP_0002896'>liver cancer</z:hpo>, 1% (95%CI 0.3-3%) for men and 0.3% (95%CI 0.1-1%) for women and for <z:e sem="disease" ids="C0476089" disease_type="Neoplastic Process" abbrv="">endometrial cancer</z:e>, 4% (95%CI 2-8%) </plain></SENT>
<SENT sid="4" pm="."><plain>There was no evidence of increased risks for <z:e sem="disease" ids="C0153633" disease_type="Neoplastic Process" abbrv="">cancers of the brain</z:e>, pancreas, kidney, lung, breast or prostate </plain></SENT>
<SENT sid="5" pm="."><plain>Monoallelic MUTYH mutation carriers with a family history of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>, such as those identified from screening multiple-case <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> families, are at increased risk of colorectal, gastric, endometrial and possibly <z:hpo ids='HP_0002896'>liver cancers</z:hpo> </plain></SENT>
</text></document>